Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Older adults living with Type 2 diabetes face more than just blood sugar concerns. New research shows some of the most ...

Ozempic is not marketed as a weight loss drug and is prescribed to those with type 2 diabetes to help manage their condition ...

Patients with T1D experienced greater reductions in risk for cardiovascular disease with empagliflozin compared with placebo.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM): As far as side effects, the most common are gastrointestinal. And right now there ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM) explains the differences between bexagliflozin and velagliflozin, and how to determine if a patient is a good candidate ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Lori Berard, RN, DCE, Diabetes Educator, Nurse Consultant, reviews SGLT2's mechanism of action and benefits and discusses how ...

Medications designed to treat diabetes by lowering blood sugar levels, like Ozempic, continue to turn up added benefits, and ...